[Thrombolytic therapy of deep venous thrombosis. Indications, treatment procedures].
Theiss
W
W
I. Medizinische Klinik und Poliklinik, Technischen Universität, Klinikum rechts der Isar, München.
D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012008:Recurrence; D013300:Streptokinase / Q000009:adverse effects / Q000627:therapeutic use; D015912:Thrombolytic Therapy / Q000379:methods*; D013924:Thrombophlebitis / Q000188:drug therapy*; D010959:Tissue Plasminogen Activator / Q000009:adverse effects / Q000627:therapeutic use; D014568:Urokinase-Type Plasminogen Activator / Q000009:adverse effects / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D013300:Streptokinase; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator
Thrombolysetherapie tiefer Venenthrombosen. Indikationsstellung, Behandlungsverfahren.